Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Hold rating and $38.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).The analyst comments "SUPN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
